GS

Gurjinder Singh

Active Director Director DIN 11782773
DIN 11782773 First appointment Jul 2026 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Gurjinder Singh

Data last updated:

Gurjinder Singh is a Director at Jamkas Pharmaceuticals Private Limited (since 2026). The company operates in Pharma.

DIN 11782773
Primary Designation Director
Industry Pharma
First Appointment 01 Jul 2026
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director01 Jul 20262021Active

Directorship timeline

Open interactive timeline →
Jamkas Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Gurjinder Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gurjinder Singh

Gurjinder Singh currently holds 1 directorship: Jamkas Pharmaceuticals Private Limited (Director, since 01 Jul 2026).

Gurjinder Singh was first appointed on 01 Jul 2026 as Director at Jamkas Pharmaceuticals Private Limited.

The current boards of Gurjinder Singh's companies include Kanav Goyal (Jamkas Pharmaceuticals Private Limited), Manish Goyal (Jamkas Pharmaceuticals Private Limited), Rakesh Kumar (Jamkas Pharmaceuticals Private Limited), Rupali Singla (Jamkas Pharmaceuticals Private Limited), Sayam Mittal (Jamkas Pharmaceuticals Private Limited), Vaneet Jain (Jamkas Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available